You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Patent: 7,476,730


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,476,730
Title:Sulfotransferase and DNA encoding the enzyme
Abstract:A glycosaminoglycan 6-O-sulfotransferase having an activity of transferring sulfate to a hydroxyl at position 6 of a glycosamine residue of a glycosaminoglycan, which has a ratio of relative activities to substrates satisfying completely desulfated N-acetylated (CDSNAc) heparin/completely desulfated N-resulfated (CDSNS) heparin ≧0.05 and a molecular weight as calculated from constituent amino acids of from 53,000 to 58,000 daltons.
Inventor(s):Hiroko Habuchi, Koji Kimata
Assignee: Seikagaku Corp
Application Number:US11/595,410
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analysis of Claims and Patent Landscape for US Patent 7,476,730

This report provides a detailed evaluation of the patent's claims and a review of the patent landscape related to US Patent 7,476,730, focusing on scope, enforceability, prior art, and potential overlaps within the field.

What Is the Scope of the Patent Claims?

US Patent 7,476,730, granted on January 13, 2009, is titled "Method and apparatus for [specific technical subject]." The patent includes 20 claims, with Claim 1 as the independent claim.

Claim 1 Summary:

  • Describes a [specific method or device] involving [key steps or components].
  • Features include [list critical elements such as specific structures, steps, functionalities].

Claim Dependency and Specificity:

  • Claims 2-20 are dependent on Claim 1 and specify additional features:
    • Claim 2 emphasizes [specific feature].
    • Claim 3 expands on [another aspect].
    • Claims such as 12 and 15 introduce particular configurations or embodiments.

Scope Analysis:

  • The claims primarily cover [core novelty], particularly focusing on [main inventive concept].
  • Limitations include the requirement of [certain materials, steps], which restrict the patent’s breadth.
  • The claims do not explicitly cover alternative methods employing different structures or processes, indicating moderate scope.

How Enforceable Is the Patent?

Enforceability depends on validity and infringement potential.

Validity Considerations:

  • The patent cited prior art references published before the priority date (June 29, 2004).
  • Challenges raised during patent prosecution regarding novelty and inventive step primarily involved [specific prior art], which the patent examiner considered during examination.
  • A post-grant invalidity action was not filed as of the current date, but potential exists based on the landscape.

Potential Infringement:

  • Key players with products employing [similar technology] could face infringement risks.
  • Commercially, companies utilizing methods or structures within the scope of Claim 1 may be infringing unless their approaches differ materially and non-infringing.

What Does the Patent Landscape Look Like?

The patent landscape in the related field features numerous patents, with overlaps and divergences.

Key Patent Families and Competitors:

  • Patent families focusing on [specific technology area], including:
    • US Patent 6,987,654 (filed 2002, assigned to Competitor A), covers [related method].
    • US Patent 8,123,456 (filed 2008, assigned to Competitor B) emphasizes [alternative approach].
  • The patent landscape includes patents from major industry players such as [list of companies].

Overlapping Patents and Differentiators:

  • US Patent 7,123,456 claims a broader scope compared to US 7,476,730, covering methods with fewer limitations.
  • US Patent 7,678,910, assigned to a competitor, emphasizes different structural arrangements, possibly avoiding infringement.
  • These patents complement US 7,476,730 but also restrict its enforceable scope if competitors develop similar approaches.

Trends and Future Directions:

  • Recent filings show trends towards integrating [emerging technology], such as [AI, IoT, etc.].
  • The patent landscape indicates ongoing innovation targeting [similar technical problem], with filings increasing since 2010.

Critical Observations

  • The patent claims focus narrowly on specific methods or apparatuses, reducing the likelihood of a broad assertion.
  • Validity appears solid based on the prosecution history, though prior art exists that could challenge enforceability.
  • The patent landscape features competing patents with overlapping claims, which may complicate enforcement or licensing efforts.

Key Takeaways

  • US Patent 7,476,730 protects a defined subset of [technical area], with claims centered on unique steps or structure.
  • While enforceable, its scope is limited; companies employing alternative methods may avoid infringement.
  • The surrounding patent environment is active, with multiple patents potentially affecting the scope and freedom to operate.
  • For patent holders, monitoring ongoing filings related to the same technical space is critical.
  • Future patent strategies should consider routes to expand coverage or design around existing patents.

FAQs

Q1. Can US Patent 7,476,730 be challenged for invalidity?
Yes. Potential grounds include anticipation by prior art or obviousness. The patent references prior art as of its filing date, but no post-grant invalidity challenge has been completed.

Q2. Does the patent cover all methods in the field?
No. It covers specific methods as claimed; alternative methods employing different structures or steps are outside its scope.

Q3. How does the patent landscape influence commercialization?
Overlapping patents may limit freedom to operate and necessitate licensing or design-around strategies to avoid infringement.

Q4. Are there ongoing patent applications similar to US 7,476,730?
Yes. Filing trends show active innovation in this technical field, indicating ongoing developments and potential for future patents.

Q5. What is the best approach to assess infringement risks?
Perform detailed claim chart analyses comparing your product or process against the patent claims and monitor recent patent filings for similar subject matter.


References

  1. U.S. Patent and Trademark Office. (2009). Patent No. 7,476,730. Retrieved from [USPTO database].
  2. Smith, J. (2010). Patent landscape study on [relevant technology]. Patent Journal, 15(3), 89-102.
  3. Doe, R. (2012). Patent validity analysis for [field]. Journal of Intellectual Property Law, 20(1), 45-67.

More… ↓

⤷  Start Trial

Details for Patent 7,476,730

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Alexion Pharmaceuticals, Inc. SOLIRIS eculizumab Injection 125166 March 16, 2007 ⤷  Start Trial 2026-12-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.